» Articles » PMID: 36712642

Novel Targeted PH-responsive Drug Delivery Systems Based on PEGMA-modified Bimetallic Prussian Blue Analogs for Breast Cancer Chemotherapy

Overview
Journal RSC Adv
Specialty Chemistry
Date 2023 Jan 30
PMID 36712642
Authors
Affiliations
Soon will be listed here.
Abstract

The development of novel nanoparticle-based drug delivery systems (nano-DDSs) with high loading capacity, low toxicity, precise targeting, and excellent biocompatibility remains urgent and important for the treatment of breast cancer (BC). Herein, novel BC-targeted nano-DDSs based on bimetallic Prussian blue analogs (PBA-DDSs) for intracellular doxorubicin (DOX) delivery and pH-responsive release were developed. Two kinds of bimetallic PBA, namely CuFe (copper-iron) PBA and CoFe (cobalt-iron) PBA, were synthesized by a coprecipitation method, followed by modification with polyethyleneglycol methacrylate (PEGMA) surface-initiated atom transfer radical polymerization and immobilization with the AS1411 aptamer to obtain two kinds of novel BC-targeted nano-DDS. CuFePBA@PEGMA@AS1411 and CoFePBA@PEGMA@AS1411 showed high drug loading efficiency of 80% and 84%, respectively, for DOX, while 56.0% and 75.9% DOX release could be achieved under acidic pH conditions. cell viability and experiments proved the good biocompatibility of both PBA-DDSs. Cellular uptake and distribution suggested that both PBA-DDSs had efficient nucleolin-targeting capability, indicating the targeted delivery of DOX in tumor tissues. evaluation of anti-BC efficacy further confirmed that the obtained PBA-DDSs exhibited excellent therapeutic efficacy with limited side-effects. Therefore, the proposed novel PBA-DDSs can be used as secure and effective drug nano-DDSs for BC chemotherapy.

Citing Articles

Prussian blue nanotechnology in the treatment of spinal cord injury: application and challenges.

Gu X, Zhang S, Ma W Front Bioeng Biotechnol. 2024; 12:1474711.

PMID: 39323764 PMC: 11422158. DOI: 10.3389/fbioe.2024.1474711.


Platinum nanoparticles-embedded single-walled carbon nanotubes as a new carrier for curcumin delivery and investigating its anticancer effect on cell line 4T1.

Mohammadi A, Bagheri F, Abutalebi Y, Aghaei A, Danafar H Heliyon. 2024; 10(13):e33703.

PMID: 39027555 PMC: 11255493. DOI: 10.1016/j.heliyon.2024.e33703.


Synthesis, Structural Analysis, and Peroxidase-Mimicking Activity of AuPt Branched Nanoparticles.

Nuti S, Fernandez-Lodeiro J, Palomo J, Capelo-Martinez J, Lodeiro C, Fernandez-Lodeiro A Nanomaterials (Basel). 2024; 14(13).

PMID: 38998771 PMC: 11243270. DOI: 10.3390/nano14131166.


Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery.

Narwade M, Shaikh A, Gajbhiye K, Kesharwani P, Gajbhiye V Biomater Res. 2023; 27(1):42.

PMID: 37149607 PMC: 10164340. DOI: 10.1186/s40824-023-00365-y.

References
1.
Benyettou F, Alhashimi M, OConnor M, Pasricha R, Brandel J, Traboulsi H . Sequential Delivery of Doxorubicin and Zoledronic Acid to Breast Cancer Cells by CB[7]-Modified Iron Oxide Nanoparticles. ACS Appl Mater Interfaces. 2017; 9(46):40006-40016. DOI: 10.1021/acsami.7b11423. View

2.
Kanamala M, Wilson W, Yang M, Palmer B, Wu Z . Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review. Biomaterials. 2016; 85:152-67. DOI: 10.1016/j.biomaterials.2016.01.061. View

3.
Qin Z, Li Y, Gu N . Progress in Applications of Prussian Blue Nanoparticles in Biomedicine. Adv Healthc Mater. 2018; 7(20):e1800347. DOI: 10.1002/adhm.201800347. View

4.
Huang C, Neoh K, Kang E . Combined ATRP and 'click' chemistry for designing stable tumor-targeting superparamagnetic iron oxide nanoparticles. Langmuir. 2011; 28(1):563-71. DOI: 10.1021/la202441j. View

5.
Tang X, Loc W, Dong C, Matters G, Butler P, Kester M . The use of nanoparticulates to treat breast cancer. Nanomedicine (Lond). 2017; 12(19):2367-2388. PMC: 5612024. DOI: 10.2217/nnm-2017-0202. View